Bladder cancer (BC) is the most common malignancy of the urinary system and the sixth most prevalent cancer in both men and women. There is currently no biomarker identified to facilitate the diagnosis of BC and which can be considered as the gold standard. The aim of this study was to determine the diagnostic significance of serum signal peptide-CUB-EGF domain-containing protein 1 (SCUBE1) levels in patients newly diagnosed with BC and to compare the sensitivity and specificity of SCUBE1 with those of carbonic anhydrases IX (CAIX), which has previously been shown to be positive in BC. SCUBE1 and CAIX levels were investigated using enzyme-linked immunosorbent assay (ELISA) in serum samples from 19 patients with bladder cancer and 25 healthy peers. Levels of both were significantly higher in the BC group compared with the control group (p=0.0001). Based on ROC analysis, SCUBE1 emerged as a sensitive test, similarly to CAIX, for identifying BC. These findings suggest that increased SCUBE1 levels may be a useful addition to clinical findings of disease in the diagnosis of BC patients.
Birincil Dil | İngilizce |
---|---|
Konular | Sağlık Kurumları Yönetimi |
Bölüm | Clinical Research |
Yazarlar | |
Erken Görünüm Tarihi | 18 Mart 2022 |
Yayımlanma Tarihi | 18 Mart 2022 |
Gönderilme Tarihi | 14 Ocak 2022 |
Kabul Tarihi | 17 Mart 2022 |
Yayımlandığı Sayı | Yıl 2022 Cilt: 39 Sayı: 2 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.